Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis

Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis

Objectives Multiple myeloma (MM) is a malignant plasma cell disorder. The most widely accepted staging system for MM is the revised International Staging System based on cytogenetic and clinical biomarkers. The circulating clonal plasma cells (CPCs) were reported to have potential prognostic impact...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jie Ma, Mengmeng Zhang, Xiaoyan Liu, Wu Ye, Jili Deng, Feifei Wu, Congli Zhang, Qingfeng Yu, Li Cao, Silin Gan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-01-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/14/1/e071548.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Characteristics and Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients in China
by: Geng C, et al.
Published: (2025-05-01)

Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma
by: Chen Hong, et al.
Published: (2025-01-01)

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: Francesca Fazio, et al.
Published: (2023-08-01)

Prognostic value of peripheral eosinophil counts in patients with newly diagnosed multiple myeloma
by: Xu Chen, et al.
Published: (2025-05-01)

Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients
by: Xu Si, et al.
Published: (2025-05-01)

A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs
by: Ye Li, et al.
Published: (2024-10-01)

Predicting survival of persons with newly-diagnosed multiple myeloma
by: Limei Zhang, et al.
Published: (2025-08-01)

Exciting New Data in Newly Diagnosed Multiple Myeloma
by: Kaveh Samii
Published: (2022-10-01)

Outcomes for unselected, newly diagnosed multiple myeloma patients
by: Jonathan T. Moore, et al.
Published: (2025-06-01)

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study
by: Dong Liang, et al.
Published: (2025-12-01)

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
by: Grace M. Ferri, et al.
Published: (2025-01-01)

P131: Optimizing FISH results in multiple myeloma: Plasma cell selection via flow cytometry
by: Carter Wright, et al.
Published: (2025-01-01)

MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
by: Fan Yang, et al.
Published: (2025-12-01)

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients
by: Linlin Huang, et al.
Published: (2024-12-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis
by: Alberto Carretero-González, et al.
Published: (2022-12-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
by: Roberto Ria, et al.
Published: (2012-01-01)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
by: Wen‐Ying Lin, et al.
Published: (2023-02-01)

IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma
by: Shuaishuai Xu, et al.
Published: (2024-12-01)

FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
by: I. V. Galtseva, et al.
Published: (2017-06-01)

In Vivo Flow Cytometry of Circulating Tumor-Associated Exosomes
by: Jacqueline Nolan, et al.
Published: (2016-01-01)

Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta‐analysis
by: Jiading Qin, et al.
Published: (2023-02-01)

Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases
by: Daria Lisina, et al.
Published: (2025-02-01)

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01)

Tregs at Diagnosis as a Potential Biomarker for Predicting High‐Risk Functionality in Newly Diagnosed Multiple Myeloma
by: Qiaolin Zhou, et al.
Published: (2025-06-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
by: Matthew J. Pianko, et al.
Published: (2025-12-01)

The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
by: Yuxin Liu, et al.
Published: (2024-10-01)

Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
by: Xiaoqing Dong, et al.
Published: (2024-12-01)

The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma
by: Ruiqi Wang, et al.
Published: (2025-08-01)

Low prognostic nutritional index predicts poor outcome in newly diagnosed angioimmunoblastic T-cell lymphoma
by: Renqin Li, et al.
Published: (2025-06-01)

Prognostic value of serum lipids in newly diagnosed acute promyelocytic leukemia
by: Shijie Wang, et al.
Published: (2025-02-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial
by: Lisa B. Leypoldt, et al.
Published: (2025-07-01)

Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
by: Deepesh P. Lad
Published: (2024-04-01)

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
by: E. Bridget Kim, et al.
Published: (2025-07-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
by: Christian Brieghel, et al.
Published: (2025-04-01)

Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study
by: Xinhe Shan, et al.
Published: (2025-05-01)